2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre A
Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Real-World Evidence
PAPER

240 A Phase 1 study of SGR-1505, an oral, potent MALT1 inhibitor with clinical activity demonstrated in relapsed/refractory B-cell malignancy populations with poor prognostic markers

Stephen E. Spurgeon, MD, Paolo Ghia, MD, PhD2, Vasile Musteata Sr, MD, PhD, MPH3, Mengyang Di, MD, PhD4, Adam J. Olszewski, MD5, Vincent Ribrag, MD6, Matthew L. Ulrickson, MD7, Ciprian Ionut Tomuleasa, MD, PhD8, Nashat Gabrail, MD9, Carlo Visco, MD10, Erika Ravelli, MD11, Michal Taszner, MD12, Daniel Morillo, MD13, Guru Subramanian Guru Murthy, MD14, Matthew McKinney, MD15, Erin Mulvey, MD16, David Sibon Sr, MD, PhD17, Andrés José María Ferreri, MD18, Damian Cubillas, MD19, Eva Gonzalez Barca, MD PhD20, Laura Calustian, M.D.21, Frank Gerard Basile, M.D.22, Kenny Pham, PharmD23, Michele Corrado24, Vipul Gupta25, Sen Zhang26, Brian Yoo, BS27, Kevin Wu, MD28, Ahmed Hamdy, MD29, Oksana Karnabeda, MD30
1 Oregon Health & Sciences University, Portland, Oregon, United States
2 Medical School, Universita Vita-Salute San Raffaele, Milan, Italy
3 ARENSIA Research Clinic at the Institute of Oncology, Chisinau, Moldova
4 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, United States
5 Brown University, Providence, Rhode Island, United States
6 Institute Gustave Roussy, Villejuif, France
7 Banner/MD Anderson Cancer Center, Gilbert, Arizona, United States
8 ARENSIA Research Clinic at the Institute of Oncology, Cluj, Romania
9 Gabrail Cancer Center, Canton, Ohio, United States
10 University of Verona, Verona, Italy
11 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
12 Medical University of Gdansk, Gdansk, Poland
13 START Madrid-FJD Early Phase Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain
14 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
15 Duke University Medical Center, Durham, North Carolina, United States
16 Weill Cornell Medicine, New York, New York, United States
17 AP-HP Hopital Henri Mondor, Creteil, France
18 IRCCS San Raffaele Scientific Institute; Ateneo Vita-Salute San Raffaele University, Milano, Italy
19 START Madrid, Madrid, Spain
20 Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain
21 ARENSIA Institutul Oncologi, Bucharest, Romania
22 Schrodinger, New York, New York, United States
23 Schrodinger, New York, New York, United States
24 Schrodinger, New York, New York, United States
25 Schrodinger, New York, New York, United States
26 Schrodinger, New York, New York, United States
27 Schrodinger, New York, New York, United States
28 Schrodinger, New York, New York, United States
29 Schrodinger, New York, New York, United States
30 ARENSIA Research Clinic at the Institute of Oncology Kyiv, Kyiv, Ukraine
Background: MALT1 is a central convergence node integrating BCR-BTK and TLR-MYD88 signaling, positioning it as a critical target for NF-κB-driven B-cell malignancies, including CLL, WM, non-GCB DLBCL, MCL and MZL. This occurs via destabilization of NF-κB signaling by preventing A20/CYLD cleavage; preventing canonical NF-κB activation by limiting RelB cleavage; suppressing IL-6 and IL-10 transcription via regnase-1/roquin cleavage; and blocking cell adhesion and microenvironmental interactions through increased BCL10 cleavage. SGR-1505 is a potent, selective inhibitor of MALT1 protease activity, while preserving the scaffold function which mitigates off-target effects observed with complete pathway suppression. SGR-1505-101 (NCT05544019) is an ongoing Phase 1 study in patients (pts) with R/R B-cell malignancies, who have received ≥2 prior lines of therapies. Safety (N=79) and efficacy data (n=72) are presented.

Methods: Pts received oral SGR-1505 daily in 21-day cycles in a modified 3+3 dose escalation design once daily (QD) or twice daily (BID). Waldenström macroglobulinemia (WM) pts were enriched using a Bayesian two-stage design with randomized dose assignment (50 mg BID and 100 mg BID) to further characterize safety, tolerability, PK and preliminary efficacy. Disease assessments occurred every 12 weeks for indolent lymphomas and WM pts and every 9 weeks for aggressive NHL pts. 

Results: As of 01-Jun-2026, 79 pts were treated at 8 dose levels across two dosing schedules (QD: 50-300 mg, BID: 50-150 mg). Subtypes enrolled were: Chronic lymphocytic leukemia (CLL) n=26, Waldenström macroglobulinemia (WM) n=17, non-germinal center B-cell diffuse large B-cell lymphoma (non-GCB DLBCL) n=10, marginal zone (MZL) n=9, mantle cell lymphoma (MCL) n=7, follicular lymphoma (FL) n=4, diffuse large B-cell lymphoma NOS (n=3), and other B-cell lymphomas (3). Median prior lines of therapy: 3 (range 2-10). Median time on SGR-1505 treatment: 3.4 months (0.5 - 37.4+). Twenty-three (23) (29%) pts remain on treatment.

The incidence of treatment-emergent adverse events (TEAE) in the overall safety population was 96% (>G3 61%); and treatment-related adverse events (TRAE) 63% (>G3 41%). Common TEAEs (≥10% pts) by preferred term were rash (grouped term) (30%), neutropenia (22%), hyperbilirubinemia (20%), fatigue (14%), and thrombocytopenia (10%); common G3/4 TEAEs include neutropenia (22%) with no febrile neutropenia, hyperbilirubinemia (14%) and rash (10%). Common AEs were reversible and manageable. No dose-limiting toxicities, treatment-related deaths, or cases of Hy’s law were observed.

Among the 72 efficacy-evaluable pts, objective response rates (ORRs) by histology were 83% (10/12) in WM, 25% (2/8) in MZL, 14% (1/7) in MCL, 12% (3/25) in CLL, and 10% (1/10) in non-GCB DLBCL. Median duration of response was 12.5 months (0.1+ to 23.5+). Among 25 CLL pts, 11 (44%) had prior exposure to both a BTKi and BCL2i (double-exposed), including 2 responders (17%). TP53 mutations by ctDNA (PGDx elio™ Plasma Complete) were identified in 100% of CLL responders. Among 12 WM pts, 9 (75%) had prior BTKi and chemoimmunotherapy (CIT) exposure, including 7 responders (78%). TP53 mutations were identified in 30%, CXCR4 in 20%, and BTK C481S in 10% of WM responders. Among 8 MZL pts, 6 (75%) had prior BTKi and CIT exposure, including 2 responders (33%). TP53 mutations were identified in 50% of responders. Among 7 MCL pts, 4 (57%) had prior BTKi and CIT exposure, including 1 responder with a TP53 mutation; and all 7 ABC-DLBCL pts (100%) had prior CIT exposure, including 1 responder with a TP53 mutation. Additional ctDNA data are forthcoming and will be updated at the meeting. At an equivalent total daily dose, BID dosing provided 34–57% higher steady-state Ctrough (exposure) than QD dosing. 

Conclusions: SGR-1505 monotherapy is well-tolerated, demonstrating an encouraging response rate and prolonged durability of response across heavily pre-treated multiple B-cell malignancies. Activity in pts with poor prognostic markers, such as mutations in TP53, CXCR4, and BTKi, as well as in double-exposed pts suggests that MALT1 inhibition is an important pathway in overcoming mechanisms of resistance to current standard-of-care. The favorable safety profile suggests feasible combinations with BTKi in multiple B-cell malignancies, and acalabrutinib combination in CLL is ongoing.

Stephen E. Spurgeon, MD: Janssen - Research Funding; Genentech - Research Funding; Astra Zeneca - Research Funding; Genmab - Research Funding; Merck - Research Funding; Incyte - Research Funding; Genentech - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony)